The Medical Letter on Drugs and Therapeutics
Apomorphine (Apokyn) for Parkinson's Disease
The full article is available to subscribers Subscriber Login   

Apomorphine (Apokyn – Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility (“off” episodes) in patients with advanced Parkinson’s disease. It has been available in Europe for many years.

ADVANCED PARKINSON’S DISEASE — Levodopa combined with carbidopa (Sinemet, and others) is effective for most patients with Parkinson’s disease during the first 2 to 5 years of treatment. As the disease progresses, however, some patients develop sudden, unpredictable fluctuations between mobility and immobility (the “on-off” effect).1

PHARMACOLOGY — Apomorphine is a potent lipophilic dopamine agonist that crosses the blood-brain barrier unchanged. It is rapidly absorbed after SC administration. The onset of action is usually within 10 to 20 minutes; the duration of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Apomorphine (Apokyn) for Parkinson's Disease
Article code: 1200b
 Electronic, downloadable article - $25